Why ALS trial monitoring matters in 2026
Amyotrophic lateral sclerosis (ALS) affects approximately 30,000 Americans and 450,000 people worldwide, with a median survival of 2–5 years from diagnosis. Despite decades of research, only four FDA-approved treatments exist — riluzole, edaravone, sodium phenylbutyrate/taurursodiol, and tofersen. The race for more effective therapies is intensifying.
The ALS trial landscape is now stratified by genetic subtype, creating a more complex competitive matrix:
- SOD1 ALS — tofersen (Biogen) approved 2023; next-gen SOD1-targeting programs and combination strategies now entering trials; represents ~2% of ALS cases but validates the ASO approach
- C9orf72 ALS/FTD — the most common genetic form (~40% of familial ALS); multiple ASO and small molecule programs from Wave Life Sciences, AstraZeneca, and others
- TDP-43 programs — targeting TDP-43 aggregation, mislocalization, and UPS impairment across sporadic and genetic ALS; one of the most active areas in 2026
- FUS ALS — aggressive early-onset form; ION-363 (tofersen successor) in trials
- Sporadic ALS approaches — neuroinflammation, mitochondrial, and glial cell targets for the ~90% of cases without identified genetic cause
- Gene therapy — AAV delivery of protective genes, gene editing approaches from Precision Biosciences and others
Track every new ALS trial automatically
The ALS pipeline is increasingly complex. Get a clean daily digest of new trials and status changes relevant to your focus areas.
Get Free AlertsWhat we monitor for ALS
Our daily ClinicalTrials.gov connection can be configured for precise ALS monitoring:
- Condition keywords: "amyotrophic lateral sclerosis", "ALS", "motor neuron disease", "MND", "Lou Gehrig", "progressive muscular atrophy"
- Genetic subtype keywords: "SOD1", "C9orf72", "TDP-43", "TARDBP", "FUS", "UBQLN2", "OPTN", "TBK1" — track any specific subtype
- Mechanism keywords: "antisense oligonucleotide ALS", "ASO motor neuron", "gene therapy ALS", "neuroinflammation ALS"
- Phase filter: Phase 1 (early competitive intelligence), Phase 2/3 (near-term competitive threats)
- Status alerts: New trial registrations, phase progressions, enrollment completions, and study terminations
The antisense oligonucleotide wave in ALS
Tofersen's approval established ASOs as a validated approach in ALS, triggering a wave of follow-on programs. The ASO competitive landscape in ALS in 2026 includes:
- Ionis Pharmaceuticals and its partners with multiple CNS-delivered ASOs in ALS subtypes
- Wave Life Sciences with allele-selective C9orf72 programs
- Multiple academic and industry programs using intrathecal delivery to silence toxic gain-of-function mutations
- New generation of ASOs with improved CNS penetration and dosing intervals entering early trials
For BD teams evaluating platform technologies or pipeline acquisitions in neurodegeneration, tracking ALS ASO trial registrations on ClinicalTrials.gov is a real-time competitive intelligence source.
Who uses ALS trial monitoring
- Neurodegenerative disease BD teams — tracking competitor programs across ALS, FTD, and related motor neuron diseases
- ALS-focused biotech investors — monitoring pipeline milestones and competitive positioning for portfolio companies
- CROs and clinical trial sites — identifying enrollment competition for active ALS studies
- ALS patient advocacy organizations — keeping patients and families informed about available trial options
- Academic neurologists — monitoring the commercial pipeline for investigator-initiated study collaboration opportunities
The ALS pipeline won't wait
Set up your ALS alert profile in 2 minutes. Daily digest with new trials, status updates, and phase transitions.
Start Free — No Credit Card295 active trials, 179 recruiting. Phases: Early Phase 1: 11, Phase 1: 48, Phase 2: 57, Phase 3: 19, Phase 4: 2.
| Top sponsor | Trials |
|---|---|
| Neuralink Corp | 6 |
| Synchron, Inc. | 3 |
| Eli Lilly and Company | 3 |
| Biogen | 3 |
| Clene Nanomedicine | 3 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Investigation on the Cortical Communication (CortiCom) System NCT03567213 | Recruiting | Completion pushed: 2026-08-31 → 2030-12-31 | 2026-08-22 |
| A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in… NCT07223723 | Active, Not Recruiting | Completion moved earlier: 2027-12-16 → 2027-05-26 | 2026-08-14 |
| Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in… NCT07571486 | Recruiting | Completion pushed: 2030-06 → 2031-07-15 | 2026-08-11 |
| Study of COYA 302 for the Treatment of ALS NCT07161999 | Recruiting | Phase changed: Phase 2 → Phase 2/3 | 2026-08-07 |
| FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS NCT07674667 | Recruiting | Recruitment opened | 2026-08-06 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search with email alerts, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches with email alerts, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.